Advertisement


Laura C. Michaelis, MD: In My Experience Question 1

COVID-19 and Cancer Care

Advertisement

How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?

Recorded April 24, 2020.



Related Videos

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 1

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?

Recorded April 24, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 6

Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic?

Recorded April 21, 2020.

Global Cancer Care
COVID-19

Giuseppe Curigliano, MD, PhD, on How COVID-19 Is Affecting Cancer Care: The View From Italy

Giuseppe Curigliano, MD, PhD, of the University of Milan, talks about how, in the face of the coronavirus pandemic, he and his fellow oncologists have altered the way they treat patients with cancer. Filmed March 24, 2020.

Hematologic Malignancies
COVID-19

William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it can help patients and providers, and how it operates and could evolve in the future. Filmed April 3, 2020.

Global Cancer Care
COVID-19

Giorgio V. Scagliotti, MD, PhD, on the Oncoming Waves of COVID-19: Italy’s Experience

Giorgio V. Scagliotti, MD, PhD, of the University of Turin, talks about the progression of COVID-19 through his community and how, in nursing homes, lack of experience dealing with a pandemic is fueling a third wave of the virus in Italy. Filmed April 15, 2020.

Advertisement

Advertisement




Advertisement